Asset Details
Do you wish to reserve the book?
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
Do you wish to request the book?
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
2025
Overview
Liquid biopsy through the analysis of circulating tumor DNA (ctDNA) is emerging as a powerful and non-invasive tool complementing tissue biopsy in lymphoma management. Whilst tissue biopsy remains the diagnostic gold standard, it fails to detect the molecular heterogeneity of the tumor’s multiple compartments and poses challenges for sequential disease monitoring. In diffuse large-B-cell lymphoma (DLBCL), ctDNA facilitates non-invasive genotyping by identifying hallmark mutations (e.g., MYD88, CD79B, EZH2), enabling molecular cluster classification. Dynamic changes in ctDNA levels during DLBCL treatment correlate strongly with progression-free survival and overall survival, underscoring its value as a predictive and prognostic biomarker. In Hodgkin’s lymphoma, characterized by a scarcity of malignant cells in tissue biopsies, ctDNA provides reliable molecular insights into tumor biology, response to therapy, and relapse risk. In primary central nervous system lymphoma, the detection of MYD88 L265P in ctDNA offers a highly sensitive, specific, and minimally invasive diagnostic option. Likewise, in aggressive T-cell lymphomas, ctDNA supports molecular profiling, aligns with tumor burden, and shows high concordance with tissue-based results. Ongoing and future clinical trials will be critical for validating and standardizing ctDNA applications, ultimately integrating liquid biopsy into routine clinical practice and enabling more personalized and dynamic lymphoma care.
Publisher
MDPI AG,MDPI
Subject
/ Biomarkers, Tumor - genetics
/ Biopsy
/ Cancer
/ Circulating Tumor DNA - blood
/ Circulating Tumor DNA - genetics
/ Ethylenediaminetetraacetic acid
/ Humans
/ Lymphoma
/ Lymphoma, B-Cell - diagnosis
/ Lymphoma, B-Cell - pathology
/ Lymphoma, T-Cell - diagnosis
/ Lymphoma, T-Cell - pathology
/ Mutation
/ Patients
/ Plasma
/ Review
/ T cells
